Gilead Sciences, Inc.

- The company expects incremental financing expenses in 2026 related to recent acquisitions (Arcellx, Ouro Medicines, Tubulis), contributing to about $400 million in incremental expenses, with a portion being financing expenses. - Despite these expenses, the company is effectively offsetting the impact with revenue outperformance and disciplined expense management. - They mention transaction financing expenses amounting to approximately $9.50 per share reflected in the EPS guidance for 2026. - There is no explicit mention of plans for new fundraising through additional debt or equity in the immediate future. - The management indicated it is less likely that they will pursue sizable M&A this year but remain open to strategic acquisitions if compelling opportunities arise. - Current financial strategy emphasizes disciplined financial management and operational expense prioritization without signaling imminent fundraising events.

- Gilead has made multiple recent strategic acquisitions: Arcellx (closed), Ouro Medicines and Tubulis (expected to close soon), adding best-in-class CAR-Ts, T cell engagers, antibody-drug conjugates, and novel technologies. - They plan to invest in clinical programs related to these acquisitions, driving a mid-single-digit percentage increase in R&D expenses for 2026. - Upfront IPR&D investments of approximately $11.8 billion are planned for 2026, including upfront payments associated with these acquisitions. - The company will focus on closing and integrating these acquisitions, maintaining strong clinical momentum. - While large M&A deals are less likely in 2026, Gilead remains open to strategic acquisitions if compelling opportunities arise. - Continued investments in product launches and pipeline development, including cell therapy (anito-cel), once-yearly HIV prevention (Yeztugo), and ADC platform expansion through Tubulis technology. - Emphasis on disciplined financial management to absorb acquisition-related expenses while maintaining margin expansion.

- HIV sales expected to grow 8% year-over-year in 2026, up from prior 6% growth guidance. - Yeztugo sales forecasted at approximately $1 billion in 2026, increased from $800 million earlier. - Total 2026 product sales anticipated between $30 billion and $30.4 billion, a $400 million increase. - Base business growth projected at 5%-6% for 2026, reflecting strong commercial momentum. - Antito-cel launch revenue expected to begin in early 2027, targeting a $3.5 billion fourth-line-plus CAR-T market. - Up to 4 additional product launches planned before end of 2026. - Five Phase III trial updates anticipated in 2026, supporting pipeline growth. - Steady market expansion in HIV prevention with Yeztugo's increased uptake in both naive and switch patient segments. - Continued commercial outperformance and disciplined expense management expected to sustain margin strength.

- Gilead expects full-year 2026 operating income of $2.4 billion to $2.9 billion, factoring in acquisitions and related expenses. - Excluding upfront payments from acquisitions, operating income is projected between $14 billion and $14.5 billion, an increase of $200 million from prior guidance. - Full-year 2026 non-GAAP loss per share is guided between $1.05 and $0.65 due to acquisition costs; excluding these, non-GAAP diluted EPS is $8.45 to $8.85, consistent with earlier guidance. - The company anticipates manageable incremental expenses in 2026 and 2027 due to acquisitions with room for margin expansion beyond 2027, supported by portfolio growth. - Expect continued strong financial performance with potential to strengthen margins over time, despite quarter-to-quarter variability. - Near-term business development focuses on integration and clinical momentum, with limited large M&A expected in 2026.

The provided document does not explicitly mention current or expected orderbook or pending orders figures. However, relevant commercial performance and outlook details include: - Strong first-quarter sales of $6.9 billion, up 5% year-over-year. - HIV commercial sales of $5 billion, up 10% year-over-year. - Yeztugo showing strong launch performance with updated $1 billion revenue guidance for 2026. - BIC/LEN anticipated launch in late August 2026 with modest revenues in 2026 and ramp in 2027. - Trodelvy showing 37% year-on-year growth. - Pipeline and acquisition-related products progressing with expected launches and approvals in 2026-2027. - Updated 2026 revenue guidance increased by $400 million reflecting 1Q outperformance and momentum. No direct data on orderbook or pending orders is disclosed in the excerpts provided.